Clinical Scorecard: Medicare Drug Price Negotiations, Generic Access, and Patient Costs for Cardiovascular Medications
At a Glance
Category
Detail
Condition
Medicare plan-level out-of-pocket costs for selected cardiovascular medications
Key Mechanisms
A plan-level difference-in-differences analysis compared 30-day out-of-pocket costs before and after implementation of Medicare price negotiation, separately for medications with and without generic alternatives; estimates are associations.
Target Population
Medicare drug coverage plans covering selected anticoagulants, SGLT2 inhibitors, ARNI, PCSK9 inhibitors, or ticagrelor; no beneficiary-level data were analyzed.
Care Setting
Medicare prescription drug coverage, including Medicare Advantage and Stand-Alone plans
Key Highlights
The repeated cross-sectional analysis included 6,215 Medicare drug coverage plans.
For medications without a generic option, price negotiation was associated with a $56.63 decrease in 30-day out-of-pocket costs (95% CI, $55.48 to $57.78).
For medications for which a generic became available, the associated decrease was $7.46 (95% CI, $6.05 to $8.78).
Costs were calculated for specified starting regimens during the initial coverage phase.
The study covered the first year after implementation and did not assess beneficiary-level costs or clinical outcomes.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
The article cites prior literature associating high out-of-pocket medication costs with poorer adherence and outcomes; this study did not assess adherence or clinical outcomes.
The analysis did not include beneficiary-level enrollment, diagnoses, or other cost barriers.
Patient & Prescribing Data
No individual beneficiaries were studied; the analysis used publicly accessible plan-level data from 6,215 Medicare drug coverage plans.
Thirty-day out-of-pocket costs were calculated for specified starting regimens. The reported association with lower costs was larger for medications without a generic option than for medications for which a generic became available.
Clinical Best Practices
The estimates are plan-level associations from a difference-in-differences analysis, not beneficiary-level cost or clinical outcome estimates.
The study was limited to the first year after implementation, selected cardiovascular medications, and 30-day costs during the initial coverage phase.
The authors identified the timing of generic entry relative to Medicare negotiation as a potential limitation of the negotiation process.
by Celeste W. Franklin, Nathalia Ladino, Neha Parvathala, Gary C. N. Hettinger, Harmony R. Reynolds, Samrachana Adhikari, Saul Blecker, Amrita Mukhopadhyay